Obesity Considerations in Pediatric Drug Development, 2016–2021
The Journal of Clinical Pharmacology · 2023
DOI: 10.1002/jcph.2305 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, 2023. Verfasst von Sherbet Samuels und 3 weiteren Autor:innen. Beteiligte Einrichtung: Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. Hauptthemen laut MEDLINE: Drug Development, Pediatric Obesity. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Pediatric obesity is a global public health concern. Obesity‐related physiological changes may affect the pharmacokinetics of drugs and lead to therapeutic failure or toxicities. An earlier review of pediatric drug development programs from 2007 to 2016 found that, of 89 programs listing obesity‐related terms, only 4 (4%) products described pharmacokinetic changes associated with obesity. This review examined obesity considerations for 185 drug products for which pediatric drug development programs were submitted to the US Food and Drug Administration (FDA) between 2016 and 2021. The FDA‐authored review documents and drug product labeling were queried for obesity‐related terms and the review found 97/185 (52%) drug products had obesity‐related terms in these sources. Of the 97 drug products, 55/97 (57%) had obesity‐related terms in the FDA‐authored reviews only, 13/97 (13%) had obesity‐related terms in the drug product labeling only, and 29/97 (30%) had obesity‐related terms in both FDA‐authored reviews and drug product labeling. Most of the obesity‐related information in the drug product labeling originated from data collected from adults. Only 13/185 (7%) drug product labeling contained obesity‐related terms in reference to drug pharmacokinetics. Specific dosage recommendations for the use of the drug products in pediatric patients who are obese remain lacking. The dearth of available information to guide drug dosages in the obese pediatric population suggests that further research, innovative approaches, and evidence‐based guidelines are needed to inform the optimal therapeutic use of drugs in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
- Office of Pharmaceutical Quality, Office of Biotechnology Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
ORCID-Profile: Kyunghun Park, Gilbert J Burckart
Zitieren
APA
Samuels, S., Bhatt-Mehta, V., Park, K., & Burckart, G. J. (2023). Obesity Considerations in Pediatric Drug Development, 2016–2021. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2305
Vancouver
Samuels S, Bhatt-Mehta V, Park K, Burckart GJ. Obesity Considerations in Pediatric Drug Development, 2016–2021. The Journal of Clinical Pharmacology. 2023. doi:10.1002/jcph.2305
BibTeX
@article{Samuels2023,
author = {Samuels, Sherbet and Bhatt-Mehta, Varsha and Park, Kyunghun and Burckart, Gilbert J},
title = {Obesity Considerations in Pediatric Drug Development, 2016–2021},
journal = {The Journal of Clinical Pharmacology},
year = {2023},
doi = {10.1002/jcph.2305}
}
EUVIMED